REZOLUTE INC. news, videos and press releases
For more news please use our advanced search feature.
REZOLUTE INC. - More news...
REZOLUTE INC. - More news...
- Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
- Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
- Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
- Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
- Rezolute Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- FDA Grants Orphan Drug Designation to Rezolute’s Ersodetug (RZ358) for the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
- Rezolute Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
- Rezolute to Participate in Upcoming Investor Conferences
- Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
- FDA Lifts Partial Clinical Holds on RZ358 for the Treatment of Congenital Hyperinsulinism and Authorizes U.S. Inclusion in Ongoing Phase 3 Study
- Rezolute to Participate in Upcoming Investor Conferences
- Rezolute Announces FDA Clearance of IND Application for Phase 3 Registrational Study of RZ358 for Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
- Rezolute to Participate in the BTIG Virtual Biotechnology Conference
- Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
- Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
- Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
- Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Rezolute to Participate in the Jefferies Global Healthcare Conference
- Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
- Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
- Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
- Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
- Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
- Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
- Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
- Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
- Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
- Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
- Rezolute Reports First Quarter Fiscal 2024 Results
- Rezolute Receives Priority Medicines (PRIME) Eligibility from European Medicines Agency for Enhanced Regulatory Support of RZ358 in Congenital Hyperinsulinism
